Allegro Ophthalmics LLC in San Juan Capistrano named Bill Link to its board.
Link is cofounder and a managing director of healthcare investment firm Versant Ventures in Menlo Park, which maintains a presence in Newport Beach through Link.
Allegro focuses on the treatment of vitreoretinal diseases. It completed a Phase 2 clinical trial last month for its Luminate therapy, which intends to treat vision loss caused by deterioration of the macula.
The macular is the central portion of the retina responsible for focusing central vision in the eye and the clinical trial results showed reduction in central macular thickness.
Macular degeneration and edema—swelling—can result from aging, diabetes, and retinal blood vessel blockage. Luminate targets cell receptors to reduce vascular leakage and inhibit new blood vessel formation.
Versant doesn’t list Allegro as a portfolio company.
